JP2015524415A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524415A5
JP2015524415A5 JP2015523297A JP2015523297A JP2015524415A5 JP 2015524415 A5 JP2015524415 A5 JP 2015524415A5 JP 2015523297 A JP2015523297 A JP 2015523297A JP 2015523297 A JP2015523297 A JP 2015523297A JP 2015524415 A5 JP2015524415 A5 JP 2015524415A5
Authority
JP
Japan
Prior art keywords
composition
myc
bcl
hematopoietic stem
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015523297A
Other languages
English (en)
Japanese (ja)
Other versions
JP6285930B2 (ja
JP2015524415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/051384 external-priority patent/WO2014015312A1/en
Publication of JP2015524415A publication Critical patent/JP2015524415A/ja
Publication of JP2015524415A5 publication Critical patent/JP2015524415A5/ja
Application granted granted Critical
Publication of JP6285930B2 publication Critical patent/JP6285930B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015523297A 2012-07-20 2013-07-19 造血コンパートメントの再構築及び自家再構築の増進 Active JP6285930B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674224P 2012-07-20 2012-07-20
US61/674,224 2012-07-20
US201361785691P 2013-03-14 2013-03-14
US61/785,691 2013-03-14
PCT/US2013/051384 WO2014015312A1 (en) 2012-07-20 2013-07-19 Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018017287A Division JP6564892B2 (ja) 2012-07-20 2018-02-02 造血コンパートメントの再構築及び自家再構築の増進

Publications (3)

Publication Number Publication Date
JP2015524415A JP2015524415A (ja) 2015-08-24
JP2015524415A5 true JP2015524415A5 (https=) 2016-08-18
JP6285930B2 JP6285930B2 (ja) 2018-02-28

Family

ID=49949289

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015523297A Active JP6285930B2 (ja) 2012-07-20 2013-07-19 造血コンパートメントの再構築及び自家再構築の増進
JP2018017287A Expired - Fee Related JP6564892B2 (ja) 2012-07-20 2018-02-02 造血コンパートメントの再構築及び自家再構築の増進
JP2019138912A Active JP6851435B2 (ja) 2012-07-20 2019-07-29 造血コンパートメントの再構築及び自家再構築の増進
JP2021037508A Active JP7122424B2 (ja) 2012-07-20 2021-03-09 造血コンパートメントの再構築及び自家再構築の増進
JP2022126200A Ceased JP2022145801A (ja) 2012-07-20 2022-08-08 造血コンパートメントの再構築及び自家再構築の増進

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018017287A Expired - Fee Related JP6564892B2 (ja) 2012-07-20 2018-02-02 造血コンパートメントの再構築及び自家再構築の増進
JP2019138912A Active JP6851435B2 (ja) 2012-07-20 2019-07-29 造血コンパートメントの再構築及び自家再構築の増進
JP2021037508A Active JP7122424B2 (ja) 2012-07-20 2021-03-09 造血コンパートメントの再構築及び自家再構築の増進
JP2022126200A Ceased JP2022145801A (ja) 2012-07-20 2022-08-08 造血コンパートメントの再構築及び自家再構築の増進

Country Status (11)

Country Link
US (4) US9789135B2 (https=)
EP (2) EP3868387A1 (https=)
JP (5) JP6285930B2 (https=)
CN (3) CN104640551A (https=)
AU (3) AU2013292330B2 (https=)
CA (2) CA3133302A1 (https=)
DK (1) DK2877189T3 (https=)
ES (1) ES2856179T3 (https=)
IL (3) IL236763B (https=)
SG (2) SG11201500429QA (https=)
WO (1) WO2014015312A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
JP6285930B2 (ja) * 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ,インク. 造血コンパートメントの再構築及び自家再構築の増進
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
HUE055583T2 (hu) 2014-09-16 2021-12-28 Sangamo Therapeutics Inc Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
EP3224617A1 (en) * 2014-11-26 2017-10-04 Oxford University Innovation Limited Detection of acute myeloid leukaemia (aml) leukaemic stem cells (lsc)
KR20190092472A (ko) * 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
EP3595683A1 (en) * 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US20200155600A1 (en) * 2017-08-03 2020-05-21 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of cancer
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) * 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
WO2024077145A1 (en) * 2022-10-05 2024-04-11 Garuda Therapeutics, Inc. Modified hematopoietic stem cells and progenies thereof

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0207147A4 (en) 1984-12-21 1988-07-14 Techniclone Res Partners METHOD OF ELECTRICAL IMMORTALIZATION OF LYMPHOID CELLS.
DE3531430A1 (de) 1985-09-03 1987-03-05 Biotest Pharma Gmbh Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4900322A (en) 1986-09-22 1990-02-13 Adams James D Blood component pooling valve and kit
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
NZ241855A (en) 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
AU781922B2 (en) 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5289858A (en) 1991-12-18 1994-03-01 Abbott Laboratories System for accommodating withdrawal of liquid from a bulk supply
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
US5580760A (en) 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
WO1995023512A1 (en) 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6713247B1 (en) 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
DE69923550T2 (de) 1998-04-08 2006-02-16 Shionogi & Co., Ltd. Verfahren um Vorläuferzellen von Osteoklasten zu isolieren und ihre Differenzierung in Osteoklasten zu induzieren.
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6451558B1 (en) 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
EP1157275A4 (en) 1999-02-28 2003-01-15 Univ Washington NOVEL TRANSDUCTION MOLECULES AND METHODS OF USING THE SAME
WO2000059540A1 (en) 1999-04-05 2000-10-12 Biocrystal Ltd. Assay kits and methods for immune complex-mediated activation involving shed antigens
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
EP1175436B1 (en) 1999-04-12 2006-10-11 Heart Biosystems GmbH Transiently immortalized cells for use in gene therapy
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
DK1228233T3 (da) 1999-11-10 2007-05-14 Rigel Pharmaceuticals Inc Fremgangsmåder og sammensætninger omfattende grönfluorescerende proteiner (GFP) fra Renilla
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20010049393A1 (en) 1999-12-07 2001-12-06 Whitehead Institute For Biomedical Research Methods for defining MYC target genes and uses thereof
WO2001087058A1 (en) 2000-05-15 2001-11-22 Sonoko Habu Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
CA2423093C (en) 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
AU2002227112A1 (en) 2000-10-30 2002-05-15 Kalobios, Inc. Affinity maturation by competitive selection
JP2004528012A (ja) 2000-11-01 2004-09-16 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改善された免疫応答を誘導し得る発現ベクターおよびこのベクターの使用方法
EP1338198B1 (en) 2000-12-01 2007-11-28 Central Institute For Experimental Animals Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
WO2002057436A2 (en) 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
US7033744B2 (en) 2001-03-16 2006-04-25 Naoya Kobayashi Method for proliferating a liver cell, a liver cell obtained thereby, and use thereof
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
CN100506978C (zh) 2001-09-21 2009-07-01 中国人民解放军军事医学科学院野战输血研究所 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
WO2003039462A2 (en) 2001-11-02 2003-05-15 Tanox, Inc. B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003068941A2 (en) 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US7211191B2 (en) 2004-09-30 2007-05-01 Thermogenesis Corp. Blood component separation method and apparatus
EP1499180A4 (en) 2002-04-16 2006-09-13 Dana Farber Cancer Inst Inc CANCER MODELS
GB2387599B (en) 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
CA2483640A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
DK1408114T3 (da) 2002-10-11 2007-05-07 Imvision Gmbh Modulære antigen-transporter molekyler (MAT-molekyler) til modulation af immunreaktioner, tilhörende konstrukter, fremgangsmåder og anvendelser
WO2004035535A2 (en) 2002-10-15 2004-04-29 Yeda Research And Development Co. Ltd. Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
JP2006509010A (ja) 2002-12-05 2006-03-16 インペリアル・カレッジ・イノベイションズ・リミテッド アポトーシスの制御
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
EP1623017B1 (en) 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
WO2005014785A2 (en) 2003-06-18 2005-02-17 The George Washington University Conditionally-immortalized hematopoietic progenitor cell lines
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
WO2005049073A2 (en) * 2003-11-19 2005-06-02 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
US7705049B2 (en) 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
WO2006137836A2 (en) 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
WO2006045064A2 (en) 2004-10-20 2006-04-27 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
WO2007067183A1 (en) 2005-12-09 2007-06-14 The Regents Of The University Of California Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
US20060156422A1 (en) 2005-01-10 2006-07-13 Medical Research Council Methods and compositions for the generation of antibodies
JP2008535823A (ja) 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
EP1876894A1 (en) 2005-04-26 2008-01-16 The Board of Trustees of the University of Illinois Nucleoside compounds and methods of use thereof
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US20070047583A1 (en) 2005-08-29 2007-03-01 Siemens Aktiengesellschaft Method for using a short address in a packet header
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
EP1942948A4 (en) 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
EP1792627A1 (en) 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
EP2134852A4 (en) 2007-03-13 2010-04-28 Nat Jewish Health PROCESS FOR THE PRODUCTION OF ANTIBODIES
EP2214670A2 (en) 2007-11-02 2010-08-11 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
WO2009149956A2 (en) 2008-06-13 2009-12-17 Life & Brain Gmbh Fusion protein and use thereof
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
PT3031907T (pt) * 2008-11-06 2021-01-28 Univ Indiana Res & Tech Corp Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20120107317A1 (en) 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
CA2849378A1 (en) 2011-09-21 2013-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nano delivery systems for sirna
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
US9750819B2 (en) 2012-05-23 2017-09-05 Ohio State Innovation Foundation Lipid nanoparticle compositions and methods of making and methods of using the same
DE102012209673A1 (de) 2012-06-08 2013-12-24 Artcline Gmbh Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation
JP6285930B2 (ja) * 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ,インク. 造血コンパートメントの再構築及び自家再構築の増進
AU2013295652B2 (en) 2012-07-27 2018-02-08 The Board Of Trustees Of The University Of Illinois Engineering T-cell receptors
CA2884309A1 (en) * 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
US20140109246A1 (en) 2012-09-24 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
RU2671897C2 (ru) 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
EP3628322A1 (en) 2013-03-01 2020-04-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EP3134515B1 (en) 2014-04-24 2019-03-27 Board of Regents, The University of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
SG11201705064XA (en) 2014-12-24 2017-07-28 Neximmune Inc Nanoparticle compositions and methods for immunotherapy
BR112018006689A2 (pt) 2015-10-02 2018-10-09 Dana Farber Cancer Inst Inc terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle
CA3011087A1 (en) 2016-01-15 2017-07-20 Berkeley Lights, Inc. Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
WO2018104909A2 (en) 2016-12-09 2018-06-14 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Similar Documents

Publication Publication Date Title
JP2015524415A5 (https=)
JP7046112B2 (ja) 改変された造血幹/前駆細胞及び非エフェクターt細胞、そしてそれらの用途
Chute Stem cell homing
JP6449199B2 (ja) ヒト促進細胞およびその使用
JP2022549007A (ja) 養子細胞療法に使用するためのcbl阻害剤および組成物
JP2015504047A5 (https=)
CN108473949A (zh) 扩增的造血干细胞/祖细胞群体的用途
RU2665359C2 (ru) Элюирующая матрица и ее применения
Czechowicz et al. Purified hematopoietic stem cell transplantation—the next generation of blood and immune replacement
Yagyu et al. A lymphodepleted non‐human primate model for the assessment of acute on‐target and off‐tumor toxicity of human chimeric antigen receptor‐T cells
Aversa et al. Haploidentical stem cell transplantation for acute leukemia
JP2022515144A (ja) オフザシェルフのダブルネガティブt細胞の産生および治療的使用
Gorin Autologous stem cell transplantation for adult acute leukemia
Voltarelli et al. Stem cell transplantation for type 1 diabetes mellitus
He et al. FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome
Powell et al. Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism
Maqbool et al. Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases
Or-Geva et al. The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT
Miyairi et al. Donor bone marrow cells are essential for iNKT cell‐mediated Foxp3+ Treg cell expansion in a murine model of transplantation tolerance
Santiago-Osorio et al. Sodium caseinate (CasNa) induces mobilization of hematopoietic stem cells in a BALB/c mouse model
JP2019205462A (ja) デスリガンドへの移植前曝露による造血前駆細胞の活性化
Voltarelli et al. Stem cell therapies for type 1 diabetes mellitus
Stone Postremission therapy in adults with acute myeloid leukemia
Horny et al. Lymph node morphology after allogeneic bone marrow transplantation for chronic myeloid leukemia: a histological and immunohistological study focusing on the phenotype of the recovering lymphoid cells
Bayraktar et al. Advances in haploidentical stem cell transplantation